Economical data and advanced prostate carcinoma: do we need new guidelines for decision making?

Rohde, Volker; Wellmann, Axel; Fogt, Franz; Weidner, Wolfgang; Katalinic, Alexander

Rohde, Volker; Wellmann, Axel; Fogt, Franz; Weidner, Wolfgang; Katalinic, Alexander.

Affiliation

Rohde V; Clinic of Urology, Justus Liebig University of Giessen, D-35393 Giessen, Germany. vrohde@gmx.de

Oncol Rep ; 9(6): 1185-8, 2002.

Article in En | MEDLINE | ID: mdl-12375016

Subject(s)

Adenocarcinoma/economics; Decision Making; Practice Guidelines as Topic; Prostatic Neoplasms/economics; Adenocarcinoma/mortality; Adenocarcinoma/therapy; Androgen Antagonists/economics; Androgen Antagonists/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/economics; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Combined Modality Therapy; Costs and Cost Analysis; Disease Progression; Gonadotropin-Releasing Hormone/economics; Health Care Costs; Humans; Incidence; Male; Orchiectomy/economics; Prostate-Specific Antigen/blood; Prostatic Neoplasms/mortality; Prostatic Neoplasms/therapy; Survival Rate; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Adenocarcinoma / Practice Guidelines as Topic / Decision Making Type of study: Guideline / Health_economic_evaluation / Incidence_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Male Language: En Journal: Oncol Rep Journal subject: NEOPLASIAS Year: 2002 Type: Article Affiliation country: Germany

Search on Google

XML

PubMed Links